Wealth Alliance Reduces Stock Holdings in Sanofi (NASDAQ:SNY)

Wealth Alliance decreased its holdings in Sanofi (NASDAQ:SNY) by 12.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,940 shares of the company’s stock after selling 2,600 shares during the quarter. Wealth Alliance’s holdings in Sanofi were worth $942,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Cardinal Capital Management lifted its stake in Sanofi by 0.3% in the fourth quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after acquiring an additional 201 shares during the period. Sage Rhino Capital LLC raised its holdings in Sanofi by 2.8% in the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock worth $468,000 after purchasing an additional 240 shares in the last quarter. Gallacher Capital Management LLC raised its holdings in Sanofi by 4.5% in the third quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock worth $307,000 after purchasing an additional 245 shares in the last quarter. Captrust Financial Advisors raised its holdings in Sanofi by 0.9% in the third quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock worth $996,000 after purchasing an additional 246 shares in the last quarter. Finally, Rise Advisors LLC raised its holdings in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SNY. Morgan Stanley began coverage on Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Sanofi presently has a consensus rating of “Hold” and an average target price of $55.00.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $45.80 on Wednesday. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The business has a fifty day moving average price of $47.56 and a 200-day moving average price of $48.71. The company has a market capitalization of $115.86 billion, a PE ratio of 19.41, a PEG ratio of 1.73 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The company had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. As a group, equities analysts expect that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio (DPR) is presently 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.